You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSalicylate-sodium
Accession NumberDB01398
TypeSmall Molecule
GroupsApproved
Description

Sodium salicylate is a sodium salt of salicylic acid. It can be prepared from sodium phenolate and carbon dioxide under higher temperature and pressure.

It is used in medicine as an analgesic and antipyretic. Sodium salicylate also acts as non-steroidal anti-inflammatory drug (NSAID) and induces apoptosis in cancer cells. It is also potential replacement for aspirin for people sensitive to it.

Structure
Thumb
Synonyms
Salsonin
External Identifiers Not Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS numberNot Available
WeightAverage: 160.1026
Monoisotopic: 160.013638701
Chemical FormulaC7H5NaO3
InChI KeyInChIKey=ABBQHOQBGMUPJH-UHFFFAOYSA-M
InChI
InChI=1S/C7H6O3.Na/c8-6-4-2-1-3-5(6)7(9)10;/h1-4,8H,(H,9,10);/q;+1/p-1
IUPAC Name
sodium 2-hydroxybenzoate
SMILES
[Na+].OC1=CC=CC=C1C([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Benzoic acid
  • Benzoyl
  • Phenol
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic alkali metal salt
  • Organic sodium salt
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIt is used in medicine as an analgesic and antipyretic. Sodium salicylate also acts as non-steroidal anti-inflammatory drug (NSAID)
PharmacodynamicsNon-steroidal anti-inflammatory drugs such as Salicylate-sodium work by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic acid to prostaglandin H2 (PGH2). PGH2, in turn, is converted by other enzymes to several other prostaglandins (which are mediators of pain, inflammation, and fever)
Mechanism of actionSalicylate-sodium is considered a non-selective COX inhibitor—that is, it inhibits two isoforms of cyclooxygenase, COX-1 and COX-2. The analgesic, antipyretic, and anti-inflammatory activity of NSAIDs appears to be achieved mainly through inhibition of COX-2, whereas inhibition of COX-1 would be responsible for unwanted effects on platelet aggregation and the gastrointestinal tract. However, the role of the individual COX isoforms in the analgesic, anti-inflammatory, and gastric damage effects of NSAIDs is uncertain and different compounds cause different degrees of analgesia and gastric damage. Salicylate-sodium directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9253
Blood Brain Barrier+0.8725
Caco-2 permeable+0.8102
P-glycoprotein substrateNon-substrate0.8015
P-glycoprotein inhibitor INon-inhibitor0.9806
P-glycoprotein inhibitor IINon-inhibitor0.9938
Renal organic cation transporterNon-inhibitor0.9134
CYP450 2C9 substrateNon-substrate0.7949
CYP450 2D6 substrateNon-substrate0.9035
CYP450 3A4 substrateNon-substrate0.7619
CYP450 1A2 substrateNon-inhibitor0.9298
CYP450 2C9 inhibitorNon-inhibitor0.9595
CYP450 2D6 inhibitorNon-inhibitor0.95
CYP450 2C19 inhibitorNon-inhibitor0.8808
CYP450 3A4 inhibitorNon-inhibitor0.9693
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9586
Ames testNon AMES toxic0.9448
CarcinogenicityNon-carcinogens0.854
BiodegradationReady biodegradable0.9624
Rat acute toxicity2.3171 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9461
hERG inhibition (predictor II)Non-inhibitor0.9832
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Sodium salicylate crystals0.09USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility48.1 mg/mLALOGPS
logP1.36ALOGPS
logP1.98ChemAxon
logS-0.52ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Salicylate-sodium.
AcarboseSalicylate-sodium may increase the hypoglycemic activities of Acarbose.
AcenocoumarolSalicylate-sodium may increase the anticoagulant activities of Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Salicylate-sodium.
AlbiglutideSalicylate-sodium may increase the hypoglycemic activities of Albiglutide.
AlogliptinSalicylate-sodium may increase the hypoglycemic activities of Alogliptin.
AlteplaseThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Alteplase.
Aminosalicylic AcidSalicylate-sodium may increase the anticoagulant activities of Aminosalicylic Acid.
Ammonium chlorideThe serum concentration of Salicylate-sodium can be increased when it is combined with Ammonium chloride.
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Salicylate-sodium.
ApixabanSalicylate-sodium may increase the anticoagulant activities of Apixaban.
ArgatrobanSalicylate-sodium may increase the anticoagulant activities of Argatroban.
BenazeprilSalicylate-sodium may decrease the antihypertensive activities of Benazepril.
BetamethasoneThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Betamethasone.
Bismuth SubsalicylateSalicylate-sodium may increase the anticoagulant activities of Bismuth Subsalicylate.
BivalirudinSalicylate-sodium may increase the anticoagulant activities of Bivalirudin.
BromocriptineSalicylate-sodium may increase the hypoglycemic activities of Bromocriptine.
BumetanideSalicylate-sodium may decrease the diuretic activities of Bumetanide.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Salicylate-sodium.
CanagliflozinSalicylate-sodium may increase the hypoglycemic activities of Canagliflozin.
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Salicylate-sodium.
CaptoprilSalicylate-sodium may decrease the antihypertensive activities of Captopril.
ChlorpropamideSalicylate-sodium may increase the hypoglycemic activities of Chlorpropamide.
CilazaprilSalicylate-sodium may decrease the antihypertensive activities of Cilazapril.
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Salicylate-sodium.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Salicylate-sodium.
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Salicylate-sodium.
CorticotropinThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Corticotropin.
Cortisone acetateThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Cortisone acetate.
Dabigatran etexilateSalicylate-sodium may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinSalicylate-sodium may increase the anticoagulant activities of Dalteparin.
DanaparoidSalicylate-sodium may increase the anticoagulant activities of Danaparoid.
DapagliflozinSalicylate-sodium may increase the hypoglycemic activities of Dapagliflozin.
DesirudinSalicylate-sodium may increase the anticoagulant activities of Desirudin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Salicylate-sodium.
DexamethasoneThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Dexamethasone.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylate-sodium.
DiclofenamideThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Diclofenamide.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylate-sodium.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Salicylate-sodium.
DiltiazemDiltiazem may increase the anticoagulant activities of Salicylate-sodium.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Salicylate-sodium.
DisopyramideSalicylate-sodium may increase the hypoglycemic activities of Disopyramide.
DulaglutideSalicylate-sodium may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Salicylate-sodium.
EdoxabanSalicylate-sodium may increase the anticoagulant activities of Edoxaban.
EmpagliflozinSalicylate-sodium may increase the hypoglycemic activities of Empagliflozin.
EnalaprilSalicylate-sodium may decrease the antihypertensive activities of Enalapril.
EnalaprilatSalicylate-sodium may increase the nephrotoxic activities of Enalaprilat.
EnoxaparinSalicylate-sodium may increase the anticoagulant activities of Enoxaparin.
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Salicylate-sodium.
ErythromycinSalicylate-sodium may increase the hypoglycemic activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Salicylate-sodium.
Ethacrynic acidSalicylate-sodium may decrease the diuretic activities of Ethacrynic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Salicylate-sodium.
ExenatideSalicylate-sodium may increase the hypoglycemic activities of Exenatide.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylate-sodium.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Salicylate-sodium.
FludrocortisoneThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Fludrocortisone.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Salicylate-sodium.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylate-sodium.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Salicylate-sodium.
Fondaparinux sodiumSalicylate-sodium may increase the anticoagulant activities of Fondaparinux sodium.
FosinoprilSalicylate-sodium may decrease the antihypertensive activities of Fosinopril.
FurosemideSalicylate-sodium may decrease the diuretic activities of Furosemide.
GliclazideSalicylate-sodium may increase the hypoglycemic activities of Gliclazide.
GlimepirideSalicylate-sodium may increase the hypoglycemic activities of Glimepiride.
GlipizideSalicylate-sodium may increase the hypoglycemic activities of Glipizide.
GlyburideSalicylate-sodium may increase the hypoglycemic activities of Glyburide.
HeparinSalicylate-sodium may increase the anticoagulant activities of Heparin.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Salicylate-sodium.
HydrocortisoneThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Hydrocortisone.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylate-sodium.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylate-sodium.
inhaled insulinSalicylate-sodium may increase the hypoglycemic activities of inhaled insulin.
Insulin AspartSalicylate-sodium may increase the hypoglycemic activities of Insulin Aspart.
Insulin degludecSalicylate-sodium may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirSalicylate-sodium may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineSalicylate-sodium may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineSalicylate-sodium may increase the hypoglycemic activities of Insulin Glulisine.
Insulin LisproSalicylate-sodium may increase the hypoglycemic activities of Insulin Lispro.
Insulin RegularSalicylate-sodium may increase the hypoglycemic activities of Insulin Regular.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylate-sodium.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylate-sodium.
LanreotideSalicylate-sodium may increase the hypoglycemic activities of Lanreotide.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Salicylate-sodium.
LiraglutideSalicylate-sodium may increase the hypoglycemic activities of Liraglutide.
LisinoprilSalicylate-sodium may decrease the antihypertensive activities of Lisinopril.
Magnesium salicylateSalicylate-sodium may increase the anticoagulant activities of Magnesium salicylate.
MecaserminSalicylate-sodium may increase the hypoglycemic activities of Mecasermin.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylate-sodium.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylate-sodium.
MetforminSalicylate-sodium may increase the hypoglycemic activities of Metformin.
MethazolamideThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Methazolamide.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Salicylate-sodium.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Methylprednisolone.
MifepristoneSalicylate-sodium may increase the hypoglycemic activities of Mifepristone.
MiglitolSalicylate-sodium may increase the hypoglycemic activities of Miglitol.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Salicylate-sodium.
MoexiprilSalicylate-sodium may decrease the antihypertensive activities of Moexipril.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Salicylate-sodium.
NadroparinSalicylate-sodium may increase the anticoagulant activities of Nadroparin.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylate-sodium.
NateglinideSalicylate-sodium may increase the hypoglycemic activities of Nateglinide.
OctreotideSalicylate-sodium may increase the hypoglycemic activities of Octreotide.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salicylate-sodium.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Salicylate-sodium.
PasireotideSalicylate-sodium may increase the hypoglycemic activities of Pasireotide.
PentamidineSalicylate-sodium may increase the hypoglycemic activities of Pentamidine.
PerindoprilSalicylate-sodium may decrease the antihypertensive activities of Perindopril.
PioglitazoneSalicylate-sodium may increase the hypoglycemic activities of Pioglitazone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylate-sodium.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Salicylate-sodium.
PramlintideSalicylate-sodium may increase the hypoglycemic activities of Pramlintide.
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Salicylate-sodium.
PrednisoloneThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Prednisolone.
PrednisoneThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Prednisone.
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Salicylate-sodium.
QuinaprilSalicylate-sodium may decrease the antihypertensive activities of Quinapril.
QuinineSalicylate-sodium may increase the hypoglycemic activities of Quinine.
RamiprilSalicylate-sodium may decrease the antihypertensive activities of Ramipril.
RepaglinideSalicylate-sodium may increase the hypoglycemic activities of Repaglinide.
Repository corticotropinThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Repository corticotropin.
ReteplaseThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Reteplase.
RivaroxabanSalicylate-sodium may increase the anticoagulant activities of Rivaroxaban.
RosiglitazoneSalicylate-sodium may increase the hypoglycemic activities of Rosiglitazone.
SalsalateSalicylate-sodium may increase the anticoagulant activities of Salsalate.
SaxagliptinSalicylate-sodium may increase the hypoglycemic activities of Saxagliptin.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Salicylate-sodium.
SitagliptinSalicylate-sodium may increase the hypoglycemic activities of Sitagliptin.
SulfadiazineSalicylate-sodium may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleSalicylate-sodium may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleSalicylate-sodium may increase the hypoglycemic activities of Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylate-sodium.
SunitinibSalicylate-sodium may increase the hypoglycemic activities of Sunitinib.
TenecteplaseThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Tenecteplase.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Salicylate-sodium.
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Salicylate-sodium.
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Salicylate-sodium.
TinzaparinSalicylate-sodium may increase the anticoagulant activities of Tinzaparin.
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Salicylate-sodium.
TolazamideSalicylate-sodium may increase the hypoglycemic activities of Tolazamide.
TolbutamideSalicylate-sodium may increase the hypoglycemic activities of Tolbutamide.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylate-sodium.
TopiramateThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Topiramate.
TorasemideSalicylate-sodium may decrease the diuretic activities of Torasemide.
TrandolaprilSalicylate-sodium may decrease the antihypertensive activities of Trandolapril.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylate-sodium.
TriamcinoloneThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Triamcinolone.
TrimethoprimSalicylate-sodium may increase the hypoglycemic activities of Trimethoprim.
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Salicylate-sodium.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Salicylate-sodium.
VerapamilVerapamil may increase the anticoagulant activities of Salicylate-sodium.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Salicylate-sodium.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Salicylate-sodium.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Salicylate-sodium.
WarfarinSalicylate-sodium may increase the anticoagulant activities of Warfarin.
ZonisamideThe risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Zonisamide.
Food InteractionsNot Available

Targets

1. Prostaglandin G/H synthase 2

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Prostaglandin G/H synthase 2 P35354 Details

References:

  1. Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. Pubmed
  2. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007 Feb;56(2):337-45. Pubmed
  3. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. Pubmed
  4. Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. Pubmed
  5. Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. Pubmed

2. Prostaglandin G/H synthase 1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. Pubmed
  2. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. Pubmed
  3. Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. Pubmed
  4. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. Pubmed
  5. Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. Pubmed
  6. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5. Pubmed
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Comments
comments powered by Disqus
Drug created on July 08, 2007 11:05 / Updated on September 16, 2013 17:14